|
DK0919544T3
(da)
*
|
1992-04-02 |
2003-09-15 |
Smithkline Beecham Corp |
Forbindelser egnede til behandling af allergiske og inflammatoriske sygdomme
|
|
AU7174794A
(en)
*
|
1993-06-18 |
1995-01-17 |
Smithkline Beecham Corporation |
Compounds
|
|
US5780667A
(en)
*
|
1993-10-01 |
1998-07-14 |
Smithkline Beecham Corporation |
Compounds, compositions and treatment of allergies and inflammation therewith
|
|
US6013827A
(en)
*
|
1994-03-11 |
2000-01-11 |
Smithkline Beecham Corporation |
Compounds
|
|
GB9404706D0
(en)
*
|
1994-03-11 |
1994-04-27 |
Smithkline Beecham Corp |
Compounds
|
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
|
EP0799182A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
DIMERES 3.3- (DISUBSTITUTED) CYCLOHEXAN-1-OL AND RELATED COMPOUNDS
|
|
ATE306260T1
(de)
*
|
1994-12-23 |
2005-10-15 |
Smithkline Beecham Corp |
Monomere der 4,4-(disubstituierten)cyclohexan-1- ole und verwandte verbindungen
|
|
ZA9510826B
(en)
*
|
1994-12-23 |
1996-06-20 |
Smithkline Beecham Corp |
3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
|
|
EP0799204A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
MONOMERS OF 1,3,3- (TRISUBSTITUE) CYCLOHEXANE AND RELATED COMPOUNDS
|
|
WO1996020161A1
(en)
*
|
1994-12-23 |
1996-07-04 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds
|
|
US5777160A
(en)
*
|
1994-12-23 |
1998-07-07 |
Smithkline Beecham Corporation |
1, 4, 4-(trisubstituted) cyclohex-1-ene dimers and related compounds
|
|
DK0828728T3
(da)
*
|
1995-05-18 |
2003-05-19 |
Altana Pharma Ag |
Phenyldihydrobenzofuraner
|
|
JPH11505539A
(ja)
*
|
1995-05-18 |
1999-05-21 |
ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルジヒドロベンゾフラン
|
|
AR004471A1
(es)
*
|
1995-05-31 |
1998-12-16 |
Smithkline Beecham Corp |
Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
US5891883A
(en)
*
|
1995-12-21 |
1999-04-06 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
|
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
|
US6288261B1
(en)
|
1998-12-18 |
2001-09-11 |
Abbott Laboratories |
Inhibitors of matrix metalloproteinases
|
|
DZ3019A1
(fr)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
|
|
US20020077276A1
(en)
*
|
1999-04-27 |
2002-06-20 |
Fredeking Terry M. |
Compositions and methods for treating hemorrhagic virus infections and other disorders
|
|
US20040220424A1
(en)
*
|
1999-08-06 |
2004-11-04 |
Smithkline Beecham Corporation |
Process for preparing acids via alpha-chloroepoxy esters
|
|
UY26268A1
(es)
*
|
1999-08-06 |
2001-01-31 |
Smithkline Beecham Corp |
Procedimiento para preparar acidos a traves de alfa-cloroep xi- esteres ley 17164 art 127
|
|
EP1671651B1
(en)
|
1999-08-21 |
2009-11-11 |
Nycomed GmbH |
Synergistic combination of pumafentrine and salmeterol
|
|
US6572794B1
(en)
|
2000-07-24 |
2003-06-03 |
Essilor International Compagnie Generale D'optique |
Method of manufacturing a photochromic molded article
|
|
FR2816950B1
(fr)
|
2000-11-17 |
2003-02-14 |
Essilor Int |
Procede d'obtention d'un latex photochromique
|
|
FR2819258B1
(fr)
|
2001-01-11 |
2003-04-11 |
Essilor Int |
Procede d'obtention d'un latex photochromique stabilise, latex obtenu et application a l'optique ophtalmique
|
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
CA2800126A1
(en)
|
2002-07-19 |
2004-01-29 |
Abbott Biotechnology Ltd. |
Treatment of tnf.alpha. related disorders
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2004087211A2
(en)
|
2003-04-01 |
2004-10-14 |
Applied Research Systems Ars Holding N.V. |
Inhibitors of phosphodiesterases in infertility
|
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20070078120A1
(en)
*
|
2003-10-21 |
2007-04-05 |
Hitoshi Ban |
Novel piperidine derivative
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
CA2898009C
(en)
|
2005-05-16 |
2018-03-27 |
Rebecca S. Hoffman |
Use of tnfa inhibitor for treatment of erosive polyarthritis
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
EP1957530A2
(en)
|
2005-10-21 |
2008-08-20 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
PL1948235T3
(pl)
|
2005-11-01 |
2014-01-31 |
Abbvie Biotechnology Ltd |
Sposób określania skuteczności adalimumabu u pacjentów cierpiących na zesztywniające zapalenie stawów kręgosłupa z zastosowaniem CTX-II i MMP-3 jako markerów biologicznych
|
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EP2738178A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
|
EP2708242A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of ankylosing spondylitis
|
|
PT2013211E
(pt)
|
2006-04-21 |
2012-06-21 |
Novartis Ag |
Derivados de purina para utilização como agonistas de receptores a2a de adenosina
|
|
NZ572765A
(en)
|
2006-06-30 |
2012-08-31 |
Abbott Biotech Ltd |
Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
|
|
EP2081933B1
(en)
|
2006-09-29 |
2011-03-23 |
Novartis AG |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
|
MX2009004715A
(es)
|
2006-10-30 |
2009-05-20 |
Novartis Ag |
Compuestos heterociclicos como agentes antiinflamatorios.
|
|
JP2010515729A
(ja)
|
2007-01-10 |
2010-05-13 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
|
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
|
WO2008127975A2
(en)
*
|
2007-04-11 |
2008-10-23 |
Alcon Research, Ltd. |
Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
|
|
CN101687851B
(zh)
|
2007-05-07 |
2013-02-27 |
诺瓦提斯公司 |
有机化合物
|
|
CA2688161C
(en)
|
2007-06-04 |
2020-10-20 |
Kunwar Shailubhai |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
KR101578235B1
(ko)
|
2007-12-10 |
2015-12-16 |
노파르티스 아게 |
유기 화합물
|
|
JP5584138B2
(ja)
|
2008-01-11 |
2014-09-03 |
ノバルティス アーゲー |
キナーゼ阻害剤としてのピリミジン類
|
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8236808B2
(en)
|
2008-06-10 |
2012-08-07 |
Novartis Ag |
Pyrazine derivatives as ENAC blockers
|
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
US20110281917A1
(en)
|
2009-01-29 |
2011-11-17 |
Darrin Stuart |
Substituted Benzimidazoles for the Treatment of Astrocytomas
|
|
BRPI1012162A2
(pt)
|
2009-04-29 |
2016-01-12 |
Abbott Biotech Ltd |
dispositivo de injeção automática
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
EA201200318A1
(ru)
|
2009-08-20 |
2012-09-28 |
Новартис Аг |
Гетероциклические оксимы
|
|
JP5721722B2
(ja)
*
|
2009-10-01 |
2015-05-20 |
アルコン リサーチ, リミテッド |
オロパタジン組成物およびその使用
|
|
EP2813227A1
(en)
|
2009-10-22 |
2014-12-17 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
WO2011075578A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
CA2789168A1
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
EP3360596A1
(en)
|
2010-04-21 |
2018-08-15 |
AbbVie Biotechnology Ltd. |
Wearable automatic injection device for controlled delivery of therapeutic agents
|
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
CN105056232A
(zh)
|
2010-06-03 |
2015-11-18 |
阿布维生物技术有限公司 |
用于治疗化脓性汗腺炎(hs)的用途和组合物
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
CN106075664B
(zh)
|
2011-01-24 |
2019-07-02 |
艾伯维生物技术有限公司 |
具有模制抓握面的自动注射装置
|
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
AU2012220572A1
(en)
|
2011-02-25 |
2013-08-29 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
DK2681236T3
(en)
|
2011-03-01 |
2018-04-16 |
Synergy Pharmaceuticals Inc |
PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
|
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
|
EA026655B1
(ru)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
JP5886433B2
(ja)
|
2011-09-16 |
2016-03-16 |
ノバルティス アーゲー |
嚢胞性線維症処置のためのヘテロ環式化合物
|
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
JP6130391B2
(ja)
|
2011-11-23 |
2017-05-17 |
インテリカイン, エルエルシー |
Mtor阻害剤を使用する強化された治療レジメン
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
CA2902348C
(en)
|
2013-02-25 |
2021-11-30 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
HK1220611A1
(zh)
|
2013-03-15 |
2017-05-12 |
Bausch Health Ireland Limited |
用於治疗胃肠道病症的组成物
|
|
CN105246482A
(zh)
|
2013-03-15 |
2016-01-13 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
|
CN113388007A
(zh)
|
2013-06-05 |
2021-09-14 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
|
BR112016002789A2
(pt)
|
2013-08-09 |
2017-11-21 |
Ardelyx Inc |
compostos e métodos para inibir transporte de fosfato
|
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
|
CN106458980A
(zh)
|
2014-04-24 |
2017-02-22 |
诺华股份有限公司 |
作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
|
|
MX2016013812A
(es)
|
2014-04-24 |
2017-03-09 |
Novartis Ag |
Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
|
|
ES2667424T3
(es)
|
2014-04-24 |
2018-05-10 |
Novartis Ag |
Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
|
|
EP3145951A1
(en)
|
2014-06-24 |
2017-03-29 |
InSight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
JP6526789B2
(ja)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
組み合わせ療法
|
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
|
WO2020048827A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Aktiengesellschaft |
1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
|
|
WO2020048828A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Pharma Aktiengesellschaft |
5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
|
|
WO2020237096A1
(en)
|
2019-05-21 |
2020-11-26 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|
|
MX2021015133A
(es)
|
2019-06-10 |
2022-01-24 |
Novartis Ag |
Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
|
|
WO2021038426A1
(en)
|
2019-08-28 |
2021-03-04 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
|
EP4515325A1
(en)
|
2022-04-26 |
2025-03-05 |
Essilor International |
Photochromic optical article having a mirror coating
|